Anastrozole is administered in postmenopausal women with hormone-sensitive breast cancer; however, it has been shown that aromatase inhibitors may lead to adverse effects in premenopausal female rats, such as dietary exemestane-induced mammary carcinogenesis [24].
![[This page as RDF]](http://data.gesis.org/somesci/static/rdf-icon.gif){kind=icon}